94. Treatment and survival of rectal cancer patients over the age of 80 years; a EURECCA international comparison

E Bastiaannet,A Breugom,L.H Iversen,L Pahlman,H Ortiz,V Valentini,L Van Eycken,H Rutten,V Lemmens,C.J.H Van De Velde

doi:10.1016/j.ejso.2014.08.090

Abstract

94. Treatment and survival of rectal cancer patients over the age of 80 years; a EURECCA international comparison

Highlights

Colorectal cancer is the second most common cancer in Europe and is the second cause of death from cancer, with an estimated number of 215 000 deaths in 2012 in Europe.[1]
Substantial variation was observed in the 5-year relative survival between European countries for rectal cancer patients aged 80+, next to a wide variation in treatment, especially in the use of preoperative radiotherapy in stage I–III patients and in the rate of patients undergoing surgery in stage IV patients
Treatment guidelines vary between countries, most agree that patients with stage I disease (T12N0M0) should undergo surgery without neoadjuvant therapy, and that patients with locoregional advanced disease stages need neoadjuvant chemoradiotherapy

Summary

Introduction

Colorectal cancer is the second most common cancer in Europe and is the second cause of death from cancer, with an estimated number of 215 000 deaths in 2012 in Europe.[1]. The outcome of rectal cancer has improved dramatically after the introduction of total mesorectal excision (TME) surgery, the recognition and evaluation of the circumferential resection margin and after the introduction of neoadjuvant chemoradiotherapy.[4,5,6,7] treatment guidelines vary between countries, most agree that patients with stage I disease (T12N0M0) should undergo surgery without neoadjuvant therapy, and that patients with locoregional advanced disease stages need neoadjuvant chemoradiotherapy. Population-based cohorts from Belgium (BE), Denmark (DK), the Netherlands (NL), Norway (NO) and Sweden (SE) were compared side by side for neighbouring countries on treatment strategy and 5-year relative survival (RS), adjusted for sex and age. CONCLUSIONS: Substantial variation was observed in the 5-year relative survival between European countries for rectal cancer patients aged 80+, next to a wide variation in treatment, especially in the use of preoperative radiotherapy in stage I–III patients and in the rate of patients undergoing surgery in stage IV patients

Methods

Results

Discussion

Conclusion